Telik, Inc. (Nasdaq: TELK) of Palo Alto, CA is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases. One development candidate is TELINTRA® (ezatiostat, TLK199) which is currently in Phase 2 clinical development for myelodysplastic syndrome, and severe chronic idiopathic neutropenia.  TELINTRA® is also being evaluated for the treatment of additional blood disorders, such as multiple myeloma or chemotherapy induced neutropenia. A second product candidate,   TELCYTA® (canfosfamide, TLK286), is a cancer cell-activated chemotherapeutic that has shown clinical activity in a Phase 2 and Phase 3 clinical trials in advanced ovarian cancer, non-small cell lung cancer, colon cancer and breast cancer.

We developed our product candidates through the use of our proprietary TRAP® technology, which enables the rapid discovery and efficient optimization of small molecule drug candidates. In addition to our internal drug development programs, we partner with select academic institutions and pharmaceutical and biotechnology companies on the application of TRAP® technology to new drug discovery programs for a range of disease targets.